Search

Your search keyword '"Shah, Urvi A"' showing total 714 results

Search Constraints

Start Over You searched for: Author "Shah, Urvi A" Remove constraint Author: "Shah, Urvi A"
714 results on '"Shah, Urvi A"'

Search Results

1. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.

3. Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

4. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

5. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

8. Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma.

10. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

11. The association between types of caregiver mental state language and toddler perspective-taking

12. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

13. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

14. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

15. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

18. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

21. Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

22. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

23. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study

26. Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma

27. Supplement use habits and perceptions in patients with plasma cell disorders.

28. Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.

31. Whole-genome landscape of adult T-cell leukemia/lymphoma

32. Destress It—Detection and Analysis of Stress Levels

34. Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy

36. Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies

37. Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy

38. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

39. Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma

42. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

44. Exploration of plasma‐activated water (PAW) as a cleaning‐in‐place (CIP) solution for fouling removal and microbial reduction.

45. Nutrition perceptions, needs and practices among patients with plasma cell disorders

46. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

47. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma

50. A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Disease Biomarkers and Delays Progression to Myeloma

Catalog

Books, media, physical & digital resources